Biotek-snakken — Juni 2024
-
En opdatering omkring Stenocare's produktpipeline https://proinvestor.com/boards/120744
-
Life Science seminar 2024 (HC Andersen Capital) i dag kl. 09:35.
Life Science seminar 2024 - Inderes
Tid: 04.06.2024, 09.35 Sprog: en Do you want to know more about the latest development in the Nordic Life Science industry? Get an update on HC Andersen Capital's view on valuation as well as presentations from listed Life ...
Inderes (www.inderes.dk)
-
Dagens aktie er Halozyme Therapeutics, Inc..................
Halozyme Therapeutics Inc er en biopharma platformsvirksomhed der forsker i, udvikler og kommercialiserer proprietære enzymer. Terapier fokuseret på humane enzymer
Fokuserer på at udvikle sine proprietære produkter inden for terapeutiske områder med udækkede medicinske behov, med fokus på onkologi, og licensere sin teknologi til biofarmaceutiske virksomheder til i fællesskab at udvikle produkter. https://proinvestor.com/boards/120777 -
Biomea Fusion falder 66% ...
Biomea Fusion Crashes 63% After FDA Puts Diabetes Treatment Studies On Hold
Biomea stock crashed Friday after the FDA placed two of the company's diabetes treatment studies on hold, citing concerns of liver toxicity.
Yahoo Finance (finance.yahoo.com)
-
Eisai : FDA Accepts SBLA On LEQEMBI For Early Alzheimer's Treatment https://proinvestor.com/investornyt/1170776/eisai-fda-accepts-sbla-on-leqembi-for-early-alzheimers-treatment
-
2 Biotech Stocks For Your June 2024 Watchlist https://proinvestor.com/investornyt/1171310/2-biotech-stocks-for-your-june-2024-watchlist
-
Även om börserna handlas på rekordnivåer, så finns det fortfarande aktier med stor potential. När Privata Affärer går igenom analytikernas svenska favoriter hittar de tre bolag som enbart får köprekommendationer och vissa aktier förväntas fördubblas i värde. https://www.borskollen.se/nyheter/27/aktierna-som-hela-analytikerkaren-gor-tummen-upp-for
-
STENOCARE udbyder nye aktier med rabat til ejere af TO2 Warrants https://proinvestor.com/boards/120865
-
With fresh $100M, Alzheon lays out strategy for Alzheimer’s approval next year https://firstwordpharma.com/story/5866062
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind